Clinical Ophthalmology (Dec 2022)
Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study – Fifty-Two-Week Outcomes
Abstract
Debdulal Chakraborty,1 Aniruddha Maiti,2 Jay U Sheth,3 Soumen Mondal,1 Subhendu Boral,1 Krishnendu Nandi,4 Tushar Kanti Sinha,1 Arnab Das1 1Department of Vitreoretinal Services, Disha Eye Hospitals, Kolkata, West Bengal, India; 2Department of Vitreoretinal Services, Global Eye Hospitals Eye, Kolkata, West Bengal, India; 3Department of Vitreoretinal Services, Shantilal Shanghvi Eye Institute, Mumbai, Maharashtra, India; 4Department of Vitreoretinal Services, Netralayam Super Speciality Eye Care Centre, Kolkata, West Bengal, IndiaCorrespondence: Debdulal Chakraborty, Department of Vitreoretinal services, Disha Eye Hospitals, Kolkata, West Bengal, India, Tel +91 9433059923, Email [email protected]: To report the 52-week real-world efficacy and safety outcomes of brolucizumab therapy for neovascular age-related macular degeneration (nAMD) in Indian eyes.Patients and Methods: A retrospective, multicentre chart analysis of 82 eyes of 82 patients with nAMD (switch therapy: 65 eyes; treatment-naïve: 17 eyes) with 52-week follow-up data was performed. Pro-re-nata re-treatment was offered based on visual and tomographic criteria. Changes in best-corrected visual acuity (BCVA), intraretinal fluid (IRF), subretinal fluid (SRF), central-subfield thickness (CST), and pigment epithelial detachment (PED) were the key outcome measures, coupled with the safety profile.Results: The mean age of the study population was 67.65 (± 10.67) years, with 57 male patients (69.5%). The study’s mean number of injections was 4.8 (± 0.77). After brolucizumab therapy, the BCVA improved significantly at weeks 4 (P< 0.001), and maintained up to week 52 (P< 0.001). The CST also reduced significantly at all the visits (Baseline: 413.6 ± 64.6 μm; 52-week: 292.37 ± 13.5 μm; P< 0.001). Significantly fewer eyes demonstrated residual SRF (P< 0.001) and IRF (P< 0.001) at all visits, starting with week 12 and continuing until week 52. The PED resolution was significant from week 24 through week 52 (P=0.004). Each of the 82 eyes received four injections of brolucizumab, with 63.4% (52 eyes) receiving a fifth dose and only 17.1% requiring a sixth. Mild intraocular inflammation (IOI) was seen in three eyes (3.66%) that resolved conservatively. One patient (1.2%) developed mild fever that subsided with oral medications.Conclusion: The 52-week BRAILLE study demonstrates that brolucizumab is effective and safe in nAMD eyes in a real-world setting. Brolucizumab treatment can reduce the therapeutic burden in patients with nAMD due to its rapid, sustained efficacy and favourable safety profile.Keywords: brolucizumab, inflammation, age-related macular degeneration
